Cirrhosis/Liver Failure News

Naltrexone was effective in achieving abstinence, reducing lapses and improving craving scores at 3 months in patients with alcohol-related cirrhosis, according to data presented at EASL Congress.

A home-based, prehabilitation program for liver transplant candidates that included financial incentives and text reminders increased walking by one-third over baseline, according to data presented at EASL Congress.

Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress.

Among patients with alcoholic-related liver disease in early stages, 15% progressed to decompensation and 22% died within 6 years, according to data presented at EASL Congress.

Researchers reported no difference in rates of infection, rebleeding and mortality when antibiotic prophylaxis was given to stable patients with Child-Pugh A cirrhosis and acute variceal bleeding.

Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results.

Children of parents with alcohol-related liver disease had up to a more than fourfold increased risk for alcohol-related hospitalization, despite a low absolute risk for developing alcohol-related liver disease.

The Dialive device significantly reduced severity of endotoxemia and improved albumin function in patients with acute-on-chronic liver failure and appears safe with careful patient monitoring, according to data in the Journal of Hepatology.

Patients with nonalcoholic fatty liver disease had a significantly greater risk for severe infection requiring hospitalization vs. the general population, with an absolute risk difference of more than 17%at 20 years after diagnosis.

In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line.